RetaCalc
Protocol library
SingleApproved OtherRegulatory LabelHigh confidenceSourced

Tesamorelin

A growth hormone-releasing factor analogue with an authorised US medicine for a narrow indication. The label does not support general weight-loss or anti-ageing use.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

Two community-provenance subcutaneous lines - an official forum AM-fasted cycle and a reported daily band. Community reports only, separate from the formulation-specific Egrifta labels and not a validated schedule.

Evidence source
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported cycle phases

Select a point for its calculation examples
  1. Start (AM fasted)
    1 mg
    Some reports begin near 1 mg because IGF-1 can rise strongly, dosing first thing in the morning fasted.
  2. AM fasted (5 on / 2 off)
    2 mg
    +1 mg
    An official forum protocol runs 1-2 mg 5 days on and 2 off for about 8 weeks, then a 3-week break.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 1 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator
Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface
One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.
BAC water selected
1 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

1 mL BAC
20 units

resulting U-100 draw

Concentration
5 mg/mL
BAC added
1 mL

Shown in the diagram. Closest of these examples to 25 units.

2 mL BAC
40 units

resulting U-100 draw

Concentration
2.5 mg/mL
BAC added
2 mL
3 mL BAC
60 units

resulting U-100 draw

Concentration
1.667 mg/mL
BAC added
3 mL

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Regulatory LabelSubcutaneousOnce daily
Adults with the authorised Egrifta WR indication

1.28 mg (0.16 mL of the labelled reconstituted solution) subcutaneously once daily

Egrifta WR uses an 11.6 mg multi-dose vial reconstituted with the supplied bacteriostatic water and is not substitutable with Egrifta SV.

View source
Regulatory LabelSubcutaneousOnce daily
Adults with the authorised Egrifta SV indication

1.4 mg (0.35 mL of the labelled reconstituted solution) subcutaneously once daily

Egrifta SV uses a 2 mg single-dose vial and the supplied sterile water. Its milligram and preparation instructions are formulation-specific.

View source
Community GuideSubcutaneous in reportsOnce daily; timing and cycling disputed
online research community reports

Reports commonly use 1-2 mg subcutaneously daily, often at bedtime or at least 90 minutes after food, with some beginning at 1 mg before moving to 2 mg

Morning, bedtime, fed and fasted timing all appear, and cycling is disputed. The channel correctly distinguishes original 2 mg Egrifta, 1.4 mg Egrifta SV and 1.28 mg Egrifta WR quantities as formulation-specific; raw/peptide-education/pe-tesamorelin.md:18-30 and 11489-11532.

View source
Regulatory LabelSubcutaneousOnce daily
Adults with HIV-associated lipodystrophy under the original Egrifta indication

2 mg subcutaneously once daily

The original FDA-approved Egrifta (tesamorelin for injection) is labelled at 2 mg subcutaneously once daily to reduce excess abdominal fat in HIV-associated lipodystrophy. This indication-specific dose does not validate cosmetic, anti-ageing or research-vial use.

View source
Community GuideSubcutaneous in reportsOnce daily; AM fasted in the protocol, timing disputed
authenticated research-forum (Peppys) reports and an official protocol

An official forum protocol pairs 1-2 mg tesamorelin subcutaneously first thing in the morning fasted, 5 days on and 2 off for about 8 weeks then a 3-week break, with 200 mcg ipamorelin; community practice ranges 0.5-2 mg daily with AM-versus-PM timing disputed

Forum provenance from an authenticated archive with usernames omitted. The archive keeps the original 2 mg Egrifta, 1.4 mg Egrifta SV and 1.28 mg Egrifta WR quantities separate as formulation-specific, states the peptide is subcutaneous only, and notes IGF-1 can rise strongly so some cap near 0.5 mg. Timing and cycling conflict rather than forming a consensus.

View source

Evidence summary

Tesamorelin has a regulated product for reducing excess abdominal fat in a defined patient population. The label states important limitations and formulation-specific instructions.

Scope

Evidence for the authorised indication must not be generalised to bodybuilding, anti-ageing or non-prescription research products.

Community provenance (Peppys)

An authenticated research-forum archive follows an official protocol that pairs 1-2 mg tesamorelin subcutaneously first thing in the morning fasted, 5 days on and 2 off for about 8 weeks then a 3-week break, alongside 200 mcg ipamorelin, while everyday reports range 0.5-2 mg daily. The archive keeps the original 2 mg Egrifta, 1.4 mg Egrifta SV and 1.28 mg Egrifta WR quantities separate as formulation-specific, states the peptide is subcutaneous only, and notes IGF-1 can rise strongly so some subjects cap near 0.5 mg. Morning-versus-evening timing and cycling are disputed rather than settled. Usernames and post numbers are omitted. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.

Warnings and contraindications

The authorised indication is narrow and requires clinical diagnosis and monitoring.
Different tesamorelin formulations are not interchangeable on a milligram-for-milligram basis.

Contraindications reported by the source

Pregnancy
Active malignancy
Disruption of the hypothalamic-pituitary axis
Organised research bench with labelled storage tray, vial rack, notebook and thermometer
A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.